|
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
Multimodal imaging is key for the early detection and monitoring of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Optical coherence tomography has recently been recommended by an international consensus to be the primary imaging method for the detection of atrophy in eyes. Once diagnosed, timely therapeutic intervention should be initiated with recently FDA-approved therapies that target components of the complement cascade. When optimally integrated into persona... |
|
Mastering Treatment-Naive nAMD
In this Master Class case, Dr. Priya Vakharia discusses the management of a 72-year-old White man with treatment-naive neovascular age-related macular degeneration. |
|
Mastering Suboptimal Treatment Response in nAMD
In this Master Class case, Dr. David Eichenbaum discusses the management of a 69-year-old White man with neovascular age-related macular degeneration who receives a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
Mastering Treatment-Refractory nAMD
In this Master Class case, Dr. Michael Singer discusses the management of an 82-year-old Hispanic man with treatment-refractory neovascular age-related macular degeneration. |
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|
GA and Advances in Imaging and Surgery: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 2 of this 2-part educational activity, updates in geographic atrophy will be discussed, along with advances... |
|
nAMD, Diabetic Eye Disease, and RVO: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 1 of this 2-part educational activity, updates in state-of-the-art management strategies for neovascular ag... |